Canton Hathaway LLC Decreases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Canton Hathaway LLC reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 25.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 601 shares of the company’s stock after selling 200 shares during the period. Canton Hathaway LLC’s holdings in Moderna were worth $231,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Baillie Gifford & Co. raised its position in Moderna by 1.2% during the 2nd quarter. Baillie Gifford & Co. now owns 45,883,213 shares of the company’s stock valued at $10,781,638,000 after purchasing an additional 545,449 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Moderna by 6.7% during the second quarter. Vanguard Group Inc. now owns 20,194,904 shares of the company’s stock valued at $4,745,398,000 after acquiring an additional 1,275,874 shares in the last quarter. State Street Corp lifted its stake in Moderna by 21.9% in the second quarter. State Street Corp now owns 7,325,576 shares of the company’s stock worth $1,721,364,000 after acquiring an additional 1,316,702 shares during the period. FMR LLC boosted its holdings in Moderna by 25.2% in the second quarter. FMR LLC now owns 7,215,019 shares of the company’s stock valued at $1,695,385,000 after acquiring an additional 1,452,440 shares in the last quarter. Finally, Coatue Management LLC increased its position in Moderna by 388.3% during the 2nd quarter. Coatue Management LLC now owns 6,140,904 shares of the company’s stock valued at $1,442,990,000 after purchasing an additional 4,883,219 shares during the period. 55.10% of the stock is currently owned by institutional investors.

In related news, President Stephen Hoge sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 2nd. The shares were sold at an average price of $393.13, for a total value of $3,931,300.00. Following the transaction, the president now owns 1,619,597 shares of the company’s stock, valued at $636,712,168.61. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Juan Andres sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 27th. The stock was sold at an average price of $398.12, for a total transaction of $1,990,600.00. Following the completion of the transaction, the insider now directly owns 5,000 shares in the company, valued at approximately $1,990,600. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 427,250 shares of company stock worth $148,469,635. Insiders own 19.40% of the company’s stock.

Several equities analysts recently issued reports on MRNA shares. SVB Leerink boosted their price target on shares of Moderna from $85.00 to $86.00 and gave the company an “underperform” rating in a research report on Friday, November 5th. Piper Sandler lowered their target price on Moderna to $348.00 and set an “overweight” rating for the company in a research note on Friday, November 5th. Deutsche Bank Aktiengesellschaft initiated coverage on Moderna in a research note on Friday, October 22nd. They issued a “sell” rating and a $250.00 price target on the stock. Jefferies Financial Group dropped their target price on shares of Moderna from $375.00 to $325.00 and set a “hold” rating on the stock in a report on Friday, November 5th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $395.00 price target on shares of Moderna in a research report on Friday, November 5th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Moderna currently has an average rating of “Hold” and an average target price of $243.93.

Shares of NASDAQ MRNA traded down $2.99 during trading on Thursday, reaching $273.39. 4,758,763 shares of the company traded hands, compared to its average volume of 13,243,272. The firm has a 50 day simple moving average of $325.92 and a 200-day simple moving average of $302.32. The company has a quick ratio of 1.25, a current ratio of 1.35 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $110.85 billion, a PE ratio of 16.76, a P/E/G ratio of 0.34 and a beta of 1.32. Moderna, Inc. has a 52-week low of $98.65 and a 52-week high of $497.49.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 4th. The company reported $7.70 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $9.49 by ($1.79). The company had revenue of $4.97 billion for the quarter, compared to analysts’ expectations of $6.29 billion. Moderna had a net margin of 59.69% and a return on equity of 121.61%. The business’s revenue was up 3065.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.59) EPS. As a group, research analysts predict that Moderna, Inc. will post 26.58 EPS for the current year.

Moderna Company Profile

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

See Also: What is the definition of market timing?

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.